Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Many Bright Ideas Technologies Inc V.MBI.H

Alternate Symbol(s):  MBGNF

Many Bright Ideas Technologies Inc. is a Canada-based company. The Company is focused on commercializing alternative non-medical technologies. The Company has not generated any revenue.


TSXV:MBI.H - Post by User

Comment by forfunon Sep 04, 2014 5:22pm
108 Views
Post# 22907377

RE:RE:RE:mbi nr!!!!

RE:RE:RE:mbi nr!!!!
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 4, 2014) - Med BioGene Inc. (TSX VENTURE:MBI) today announced the receipt of proxies for MBI's upcoming annual and special meeting to be held on September 5, 2014.

To date, MBI shareholders have submitted to the company's transfer agent proxies representing 41,487,681 common shares, being approximately 52% of the company's outstanding shares.

Of that amount, proxies representing approximately 18.5 to 18.7 million common shares authorizes management to vote in favour of the current directors, whereas proxies representing approximately 22 million common shares provides discretionary voting authority to Mr. Iain Weir-Jones.

As previously announced, Mr. Weir-Jones has provided to MBI advance notice of his intention to nominate four individuals for election to the board of directors of MBI. If at the Meeting Mr. Weir-Jones nominates these four individuals as previously indicated and as proxy-holder votes for their election as directors, and no further proxies are received by the company and accepted at the Meeting by the Chair, then the four nominated by Mr. Weir-Jones will be elected to the board of directors of MBI in replacement of the current directors. Under such circumstances, MBI's Executive Chairman, Erinn Broshko, and Chief Financial Officer, Scott Davis, have advised MBI that they intend to resign their positions effective upon completion of the Meeting.

If the nominees of Mr. Weir-Jones are elected at the Meeting, the directors and management of MBI congratulate them and wish them the very best. We trust that these nominees are aligned with MBI's shareholders and commercial partner, Precision Therapeutics, in their desire to see GeneFx Lung brought to market. Most importantly, MBI and Precision have a special opportunity to make this critical test available to patients suffering from lung cancer who would benefit from better-informed and more personalized treatment decisions.


This is ridiculous.  A random group is going to come in, wipe out current management and start over with little to no experience in the matters at hand, bankrupting us in the meantime.

Bullboard Posts